Tailored Systemic Therapy for the Elderly Woman

[1]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Tsuda,et al.  Histopathological assessment of anastrozole versus tamoxifen as preoperative treatment in postmenopausal women with T2-4b, N0-2, M0 breast cancer: Results from a randomized, double-blind study , 2005 .

[3]  J. Forbes,et al.  BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer , 2005 .

[4]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[5]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Wallwiener,et al.  Neoadjuvant endocrine therapy in primary breast cancer. , 2004, Clinical breast cancer.

[7]  J L Pater,et al.  Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[9]  D. R. Lewis,et al.  Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. , 2003, The oncologist.

[10]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[11]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[14]  W. Gradishar,et al.  Advances in adjuvant chemotherapy for breast cancer: the role of taxanes. , 2003, The Journal of the National Comprehensive Cancer Network.

[15]  T. Lash,et al.  Advanced age and adjuvant tamoxifen prescription in early‐stage breast carcinoma patients , 2002, Cancer.

[16]  R. Sainsbury.  Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial , 2002 .

[17]  M. Bonetti,et al.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.

[18]  G. Hortobagyi,et al.  Neoadjuvant chemotherapy for operable breast cancer. , 2002, Oncology.

[19]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Velanovich,et al.  Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients. , 2002, Journal of the American College of Surgeons.

[21]  A. Naeim,et al.  Geriatric syndromes and assessment in older cancer patients. , 2001, Oncology.

[22]  R. Gelber,et al.  Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis , 2001, The Lancet.

[23]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[24]  C. Shapiro,et al.  Side effects of adjuvant treatment of breast cancer. , 2001, The New England journal of medicine.

[25]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[26]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[27]  C. Loprinzi,et al.  Understanding the utility of adjuvant systemic therapy for primary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V. Kataja,et al.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. Cavalli,et al.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[31]  G. Lyman,et al.  What threshold for adjuvant therapy in older breast cancer patients? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[33]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[34]  M. Somerfield,et al.  American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Shapiro,et al.  Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[37]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[38]  E. Vries,et al.  Dose intensity of standard adjuvant cmf with G-CSF for premenopausal node-positive breast cancer patients. , 1998 .

[39]  J. Manola,et al.  No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[41]  R. Yancik.  Cancer burden in the aged , 1997, Cancer.

[42]  Corcoran,et al.  Polypharmacy in the Older Patient With Cancer. , 1997, Cancer control : journal of the Moffitt Cancer Center.

[43]  M. Corcoran.  Polypharmacy in the Older Patient with Cancer: The plethora of medications taken by older patients with cancer increases the risk of harmful drug interactions. , 1997 .

[44]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Matsumoto,et al.  Relaxant responses by optical isomers of ephedrine and methylephedrine in guinea pig tracheal smooth muscle. , 1996, Pharmacology.

[46]  E. D. de Vries,et al.  Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. , 1996, Oncology.

[47]  E. Trimble,et al.  Representation of older patients in cancer treatment trials , 1994 .

[48]  S. Milani,et al.  Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. , 1994, Anticancer research.

[49]  W. Satariano,et al.  The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer , 1994, Annals of Internal Medicine.

[50]  H Volk,et al.  Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  L. Case,et al.  Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. , 1992, JAMA.

[52]  I. Ellis,et al.  Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. , 1992, European journal of cancer.

[53]  L. Fallowfield,et al.  Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone , 1991, The British journal of surgery.

[54]  B Fisher,et al.  Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  R Yancik,et al.  Breast cancer in aging women. A population‐based study of contrasts in stage, surgery, and survival , 1989, Cancer.